

Ruben T H M Larue

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8250116/publications.pdf>

Version: 2024-02-01

13
papers

4,183
citations

687363

13
h-index

1125743

13
g-index

13
all docs

13
docs citations

13
times ranked

6019
citing authors

#	ARTICLE	IF	CITATIONS
1	Radiomics: the bridge between medical imaging and personalized medicine. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 749-762.	27.6	3,216
2	Quantitative radiomics studies for tissue characterization: a review of technology and methodological procedures. <i>British Journal of Radiology</i> , 2017, 90, 20160665.	2.2	270
3	Influence of gray level discretization on radiomic feature stability for different CT scanners, tube currents and slice thicknesses: a comprehensive phantom study. <i>Acta Oncol³gica</i> , 2017, 56, 1544-1553.	1.8	183
4	Decision support systems for personalized and participative radiation oncology. <i>Advanced Drug Delivery Reviews</i> , 2017, 109, 131-153.	13.7	113
5	Decision Support Systems in Oncology. <i>JCO Clinical Cancer Informatics</i> , 2019, 3, 1-9.	2.1	85
6	4DCT imaging to assess radiomics feature stability: An investigation for thoracic cancers. <i>Radiotherapy and Oncology</i> , 2017, 125, 147-153.	0.6	61
7	Modern clinical research: How rapid learning health care and cohort multiple randomised clinical trials complement traditional evidence based medicine. <i>Acta Oncol³gica</i> , 2015, 54, 1289-1300.	1.8	59
8	Pre-treatment CT radiomics to predict 3-year overall survival following chemoradiotherapy of esophageal cancer. <i>Acta Oncol³gica</i> , 2018, 57, 1475-1481.	1.8	58
9	Hypoxia and hypoxia response-associated molecular markers in esophageal cancer: A systematic review. <i>Methods</i> , 2017, 130, 51-62.	3.8	42
10	Feasibility of CT radiomics to predict treatment response of individual liver metastases in esophagogastric cancer patients. <i>PLoS ONE</i> , 2018, 13, e0207362.	2.5	31
11	A qualitative synthesis of the evidence behind elective lymph node irradiation in oesophageal cancer. <i>Radiotherapy and Oncology</i> , 2014, 113, 166-174.	0.6	22
12	A phase 1 â€œwindow-of-opportunityâ€™ trial testing evofosfamide (TH-302), a tumour-selective hypoxia-activated cytotoxic prodrug, with preoperative chemoradiotherapy in oesophageal adenocarcinoma patients. <i>BMC Cancer</i> , 2016, 16, 644.	2.6	22
13	External validation of a prognostic model incorporating quantitative PET image features in oesophageal cancer. <i>Radiotherapy and Oncology</i> , 2019, 133, 205-212.	0.6	21